OncoSec Medical Inc ONCS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 23, 2021 (filed on Aug 25, 2021)

Insider Name:

Dalesandro Margaret

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

20,000

Price:

$1.89
Aug 02, 2021 (filed on Aug 03, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-412

Price:

$2.18
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Demesa James M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

35,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

33,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-13,613

Price:

$3.16
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

192,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Smith Kevin Raymond Merrill

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Zhou Chao

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Lyerly Herbert Kim

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--

Filings by filing date

Aug 23, 2021 (filed on Aug 25, 2021)

Insider Name:

Dalesandro Margaret

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

20,000

Price:

$1.89
Aug 02, 2021 (filed on Aug 03, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-412

Price:

$2.18
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Demesa James M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

35,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

33,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-13,613

Price:

$3.16
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

192,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Smith Kevin Raymond Merrill

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Zhou Chao

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jun 28, 2021 (filed on Jun 29, 2021)

Insider Name:

Lyerly Herbert Kim

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	24 N Main St PENNINGTON NJ 08534-2218
Tel:	N/A
Website:	oncosec.com
IR:	See website

Key People

Margaret Dalesandro Independent Chairman of the Board	Robert J. Delaversano Vice President, Principal Accounting Officer, Controller	Joe Smith Vice President - Business Development

Business Overview

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company's lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Financial Overview

For the nine months ended 30 April 2021, OncoSecMedical Inc revenues was not reported. Net loss decreasedless than 1% to $33.4M. Net income also reflects Generaland administrative - Balancing decrease of 54% to $6.7M(expense), Foreign currency exchange loss, net increasefrom $257K (expense) to $187K (income), offset by Researchand development - Balancing increase of 47% to $24.7M(expense).

Employees:	42 as of Jul 31, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$31.42M as of Apr 30, 2021
Annual revenue (TTM):	$0.00M as of Apr 30, 2021
EBITDA (TTM):	-$44.44M as of Apr 30, 2021
Net annual income (TTM):	-$42.34M as of Apr 30, 2021
Free cash flow (TTM):	-$43.25M as of Apr 30, 2021
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	39,185,251 as of Jun 11, 2021
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

OncoSec Medical Inc (OQ:ONCS)